Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients

Pediatric Infectious Disease Journal

Volumn 26, Issue 12, 2007, Pages 1089-1093

  Chávez Bueno, Susana ^a,c   Mejías, Asunción ^a   Merryman, Ruth A ^b   Ahmad, Naveed ^b   Jafri, Hasan S ^a   Ramilo, Octavio ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CHILDREN S MEDICAL CENTER   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Immunocompromised children; Palivizumab; RSV therapy

Indexed keywords

PALIVIZUMAB; RIBAVIRIN;

ADOLESCENT; AEROSOL; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPOXEMIA; INFANT; INTENSIVE CARE UNIT; INTUBATION; LOWER RESPIRATORY TRACT INFECTION; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NEWBORN; PEDIATRIC HOSPITAL; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SCHOOL CHILD; SINGLE DRUG DOSE; VIRUS INFECTION;

EID: 36549025031     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181343b7e     Document Type: Article

References (37)

1. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143:S127-S132.
2. Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med. 2002;96(Suppl B):S1-S7.
3. Stensballe LG, Devasundaram JK, Simoes EA. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J. 2003;22:S21-S32.
4. Navas L, Wang E, de Carvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr. 1992;121:348-354.
5. Altman CA, Englund JA, Demmler G, et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol. 2000;21:433-438.
6. Emerick K, Cunningham M, Hartnick C. The potential impact of palivizumab on pediatric airway reconstruction. Am J Otolaryngol. 2006;27:9-12.
7. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr. 2003;143:S112-S117.
8. Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J. 2003;22:S40-S44; discussion S44-S45.
9. Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 1995;16:393-399.
10. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis. 1992;165:987-993.
11. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22:778-782.
12. Abdallah A, Rowland KE, Schepetiuk SK, et al. An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant. 2003;32:195-203.
13. Ebbert JO, Limper AH. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration. 2005;72:263-269.
14. Raboni SM, Nogueira MB, Tsuchiya LR, et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation. 2003;76:142-146.
15. McCarthy AJ, Kingman HM, Kelly C, et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. Bone Marrow Transplant. 1999;24:1315-1322.
16. Sparrelid E, Ljungman P, Ekelof-Andstrom E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant. 1997;19:905-908.
17. Groothuis JR, Woodin KA, Katz R, et al. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr. 1990;117:792-798.
18. Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med. 1991;325:24-29.
19. Ventre K, Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev. 2004:CD000181.
20. Siber GR, Leombruno D, Leszczynski J, et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis. 1994;169:1368-1373.
21. The PREVENT Study group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99:93-99.
22. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1442-1446.
23. Saez-Llorens X, Moreno MT, Ramilo O, et al. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004;23:707-712.
24. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant. 2000;25:751-755.
25. Ghosh S, Champlin RE, Ueno NT, et al. Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant. 2001;28:271-275.
26. Rodriguez WJ, Gruber WC, Groothuis JR, et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics. 1997;100:937-942.
27. Rodriguez WJ, Gruber WC, Welliver RC, et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics. 1997;99:454-461.
28. Adams R, Christenson J, Petersen F, et al. Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV. Bone Marrow Transplant. 1999;24:661-664.
29. De Vincenzo JP, Leombruno D, Soiffer RJ, et al. Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. Bone Marrow Transplant. 1996;17:1051-1056.
30. Flynn JD, Akers WS, Jones M, et al. Treatment of respiratory syncytial virus pneumonia in a lung transplant recipient: case report and review of the literature. Pharmacotherapy. 2004;24:932-938.
31. Small TN, Casson A, Malak SF, et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:321-327.
32. DeVincenzo JP, Hirsch RL, Fuentes RJ, et al. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience. Bone Marrow Transplant. 2000;25:161-165.
33. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176:1215-1224.
34. Johnson S, Griego SD, Pfarr DS, et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis. 1999;180:35-40.
35. Malley R, DeVincenzo J, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 1998;178:1555-1561.
36. Boeckh M, Berrey MM, Bowden RA, et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001;184:350-354.
37. Community-acquired respiratory viruses. Am J Transplant. 2004;4(Suppl 10):105-109.